Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Arrowhead Pharmaceuticals Inc ARWR

Healthcare Biotechnology
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform... see more

Recent & Breaking News (NDAQ:ARWR)

Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences

Business Wire May 31, 2024

Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia

Business Wire May 29, 2024

Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia

Business Wire May 28, 2024

Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma

Business Wire May 20, 2024

Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results

Business Wire May 9, 2024

Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma

Business Wire May 2, 2024

Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences

Business Wire April 29, 2024

Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars

Business Wire April 26, 2024

Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results

Business Wire April 24, 2024

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease

Business Wire April 24, 2024

Turnstone Biologics Appoints William Waddill to its Board of Directors

GlobeNewswire April 16, 2024

Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo

Business Wire April 7, 2024

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Business Wire April 1, 2024

Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data

Business Wire March 25, 2024

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy

Business Wire March 8, 2024

Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences

Business Wire March 4, 2024

Arrowhead Pharmaceuticals Reports Fiscal 2024 First Quarter Results

Business Wire February 6, 2024

Arrowhead Pharmaceuticals to Webcast Fiscal 2024 First Quarter Results

Business Wire January 22, 2024

Arrowhead Pharmaceuticals Closes Underwritten Offering with Gross Proceeds of $450.0 Million

Business Wire January 5, 2024

Arrowhead Pharmaceuticals Announces Pricing of $450.0 Million Underwritten Offering of Common Stock

Business Wire January 3, 2024